ReviewNeuro-oncology2018
Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.
Review in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Primary Intracranial High Grade Congenital Glial Lesions (PIHGCL): A systematic review of case reports from 1985 to 2025.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Surgical identification of brain tumour margins through impedance monitoring and electrocorticography and the potential for their combined use: A systematic review.Neurosurgical review · 2024Pooled it
- Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.Neuro-oncology · 2023Pooled it
- Reliability of intraoperative ultrasound in detecting tumor residual after brain diffuse glioma surgery: a systematic review and meta-analysis.Neurosurgical review · 2020Pooled it
- Molecular features unique to circulating tumor DNA enable the tumor-naïve liquid biopsy of glioblastoma.NPJ precision oncology · 2026Article
- Imaging in Neuro-oncology.Seminars in neurology · 2025Review
- Potential impact of [Radiation oncology (London, England) · 2025Article
- Impact of corticosteroid administration on contrast-enhancing volume and diffusion MRI in treatment naïve glioblastoma.Neuro-oncology · 2025Article
- Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes.Neuro-oncology · 2025Article
- Editorial: Updates on the management of glioblastoma.Frontiers in oncology · 2025Article
- Interstitial fluid transport dynamics predict glioblastoma invasion and progression.npj biomedical innovations · 2025Article
- Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.CNS oncology · 2024Article
- 1H-MRS parameters in non-enhancing peritumoral regions can predict the recurrence of glioblastoma.Scientific reports · 2024Article
- A novel methodology for mapping interstitial fluid dynamics in murine brain tumors using DCE-MRI.Methods (San Diego, Calif.) · 2024Article
- Cluster-based prognostication in glioblastoma: Unveiling heterogeneity based on diffusion and perfusion similarities.Neuro-oncology · 2024Article
- Summary of Key Points of the Response Assessment in Neuro-Oncology (RANO) 2.0.Korean journal of radiology · 2024Article
- Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes.Biomedicines · 2024Article
- Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.Journal of neuro-oncology · 2024Article
- Radiomic profiling for insular diffuse glioma stratification with distinct biologic pathway activities.Cancer science · 2024Article
- Clustering Functional Magnetic Resonance Imaging Time Series in Glioblastoma Characterization: A Review of the Evolution, Applications, and Potentials.Brain sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The use of contrast enhancement within the brain on CT or MRI has been the gold standard for diagnosis and therapeutic response assessment in malignant gliomas for decades. The use of contrast enhancing tumor size, however, remains controversial as a tool for accurately diagnosing and assessing treatment efficacy in malignant gliomas, particularly in the current, quickly evolving therapeutic landscape. The current article consolidates overwhelming evidence from hundreds of studies in the field of neuro-oncology, providing the necessary evidence base and specific contexts of use for consideration of contrast enhancing tumor size as an appropriate surrogate biomarker for disease burden and as a tool for measuring treatment response in malignant glioma, including glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.